STIM
What one share of Neuronetics holds
Surgical and Medical Instruments and Apparatus
Neuronetics, Inc. (the “Company” or “Neuronetics” or the “Registrant”) believes that mental health is as important as physical health. As a global leader in neuroscience, the Company is delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results.
Neuronetics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.22 |
|---|---|
| Profit | −$0.44 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.16 |
| Cash and investments | $0.25 |
| Debt | $0.81 |
| Book value | $0.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $234.44 | −$76.95 | $2.22 | −$60.72 | — | −$1,213 |
| 2017 | $217.38 | −$86.34 | $3.19 | −$63.11 | — | −$833.99 |
| 2018 | $5.90 | −$2.69 | $0.11 | −$2.41 | — | $4.00 |
| 2019 | $3.41 | −$1.58 | $0.04 | −$1.70 | — | $2.57 |
| 2020 | $2.61 | −$1.46 | $0.04 | −$1.55 | — | $1.33 |
| 2021 | $2.17 | −$1.22 | $0.09 | −$1.19 | — | $3.23 |
| 2022 | $2.42 | −$1.38 | $0.12 | −$1.26 | — | $2.09 |
| 2023 | $2.49 | −$1.05 | $0.08 | −$1.20 | — | $1.18 |
| 2024 | $2.36 | −$1.38 | $0.05 | −$1.02 | — | $0.50 |
| 2025 | $2.26 | −$0.59 | $0.01 | −$0.32 | — | $0.32 |